Anixa Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 30, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Net Income	-10.12	-11.03	-12.7	-9.93	-13.77	-13.13
Depreciation & Amortization	0.04	0.04	0.04	0.05	0.04	0.06
Stock-Based Compensation	3.23	3.81	4.8	4.74	6.75	8.06
Other Adjustments	0.01	-0.14	-	-	-	-0.01
Change in Receivables	-	0.17	0.1	-0.22	-0.03	-
Changes in Accounts Payable	-0.03	-0.36	0.32	-0.06	0.13	-0.1
Changes in Accrued Expenses	-0.36	-0.19	0.18	0.04	0.63	0.19
Changes in Other Operating Activities	0.18	0.52	-0.07	-0.82	-0.25	-0.02
Operating Cash Flow	-7.12	-7.17	-7.34	-6.21	-6.49	-4.94
Sale of Property, Plant & Equipment	-	-	-	-	-	0.04
Purchases of Investments	-44.07	-44.36	-63.77	-44.41	-22.49	-16.5
Proceeds from Sale of Investments	45.54	49.23	68.05	38.81	11.76	12.54
Other Investing Activities	-	-	-	-	-	0.01
Investing Cash Flow	1.47	4.87	4.28	-5.6	-10.73	-3.92
Issuance of Common Stock	5.31	2.28	3.42	0.37	0.45	31.57
Repurchase of Common Stock	-	-	-0.01	-	-	-
Net Common Stock Issued (Repurchased)	5.31	2.28	3.42	0.37	0.45	31.57
Financing Cash Flow	5.21	2.28	3.42	0.37	0.45	31.57
Net Cash Flow	-0.43	-0.03	0.36	-11.45	-16.77	22.71
Free Cash Flow	-7.12	-7.17	-7.34	-6.21	-6.49	-4.94
FCF Margin	-	-	-	-2956.67%	-	-964.45%
Free Cash Flow Per Share	-0.22	-0.22	-0.23	-0.20	-0.21	-0.17
Levered Free Cash Flow	-10.21	-10.91	-12.09	-10.6	-13.04	-12.82
Unlevered Free Cash Flow	-10.85	-11.69	-13.37	-11.8	-13.32	-13

SEC Filings: 10-K · 10-Q